University of Kentucky/Markey Cancer Center

Summary

University of Kentucky/Markey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Lung Cancer, Brain Tumor, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. University of Kentucky/Markey Cancer Center is involved with conducting 540 clinical trials across 616 conditions. There are 33 research doctors associated with this hospital, such as James T. Badgett, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.

Top PIs

Clinical Trials running at University of Kentucky/Markey Cancer Center

Lung Cancer

Skin Cancer

Pancreatic Cancer

Breast Cancer

Bladder Cancer

Breast cancer

Esophageal cancer

Cervical Cancer

Testicular cancer

Cancer

ONC-392 vs Chemotherapy

for Lung Cancer

This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.

Recruiting

2 awards

Phase 3

10 criteria

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.

Recruiting

2 awards

Phase 3